CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma...
Phase 1, Phase 2
Duarte, California, United States and 20 other locations
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)...
Phase 1, Phase 2
Los Angeles, California, United States and 6 other locations
This is a single-arm, open-label phase II clinical trial in which approximately 55 patients with newly diagnosed glioblastoma (GBM)...
Phase 2
Santa Monica, California, United States and 7 other locations
The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM...
Phase 3
Los Angeles, California, United States and 85 other locations
In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local con...
Phase 4
Los Angeles, California, United States and 10 other locations
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/II....
Phase 2, Phase 3
Los Angeles, California, United States and 60 other locations
therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The patients' own cancer cells collected after sur...
Phase 2, Phase 3
Los Angeles, California, United States and 4 other locations
with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.The names of the study drugs involved in this study are:Niv...
Phase 1
Los Angeles, California, United States and 3 other locations
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent glioma...
Phase 2
Los Angeles, California, United States and 80 other locations
as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma...
Phase 1
Los Angeles, California, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal